{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:56:12Z","timestamp":1793318172597,"version":"4.5.0"},"reference-count":26,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["No award\/grant number"],"award-info":[{"award-number":["No award\/grant number"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2026,3,14]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blood eosinophils (EOS) and fractional exhaled nitric oxide (FeNO) are potential biomarkers for disease progression and treatment response in asthma and chronic obstructive pulmonary disease (COPD). We investigated their association with exacerbations in asthma, COPD and asthma+COPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>NOVEL observational longiTudinal studY is a multicountry prospective study of patients with physician-assigned asthma, COPD and asthma+COPD. Negative binomial and logistic regression analyses were performed for baseline EOS\/FeNO (separately and combined), by diagnosis, and for different exacerbation subtypes (all, antibiotics-only, oral corticosteroids (OCS)-only).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Higher baseline EOS was significantly associated with increased risk of all exacerbations in asthma (incidence rate ratio (IRR) 1.09, 95% CI 1.01 to 1.18, p=0.033), with a trend increase with COPD (IRR 1.09, 95%\u2009CI 1.00 to 1.19, p=0.069) but not asthma+COPD. Higher baseline FeNO was significantly associated with decreased risk of all exacerbations in COPD (IRR 0.91, 95%\u2009CI 0.84 to 0.99, p=0.025) and increased risk of OCS-only exacerbations in asthma (OR 1.16, 95%\u2009CI 1.04 to 1.29, p=0.006) and asthma+COPD (OR 1.55, 95%\u2009CI 1.22 to 1.97, p&lt;0.001). In exacerbation risk in asthma (IRR 1.14, 95%\u2009CI 1.05 to 1.24, p=0.003), while in COPD, both higher EOS (IRR 1.12, 95%\u2009CI 1.02 to 1.24, p=0.033) and lower FeNO (IRR 0.87, 95%\u2009CI 0.78 to 0.96, p=0.009) were independently associated with exacerbation risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Higher EOS predicted exacerbations in asthma and COPD, while FeNO showed heterogeneous associations, particularly for OCS-only treated exacerbations. Assessment of exacerbation subtype might improve personalised management. Interpretation is limited by physician-assigned diagnoses, potential ICS confounding and recall bias.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2025-223646","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:20:35Z","timestamp":1776792035000},"page":"thorax-2025-223646","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Association of blood eosinophils and exhaled nitric oxide with exacerbations in patients with asthma, COPD and asthma+COPD: the NOVELTY study"],"prefix":"10.1136","clinical-trial-number":[{"clinical-trial-number":"nct02760329","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1927-7646","authenticated-orcid":false,"given":"Susan","family":"Muiser","sequence":"first","affiliation":[{"name":"Department of Pulmonology, University Medical Centre Groningen, Groningen, Netherlands"},{"name":"University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"M\u00fcllerov\u00e1","sequence":"additional","affiliation":[{"name":"Respiratory & Immunology, Medical and Payer Evidence Strategy, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Belton","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca, Cambridge, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nifasha","family":"Rusibamayila","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca, Cambridge, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Erhard","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca, Cambridge, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvar","family":"Agusti","sequence":"additional","affiliation":[{"name":"Respiratory Institute, Clinic Barcelona, FCRB-IDIBAPS, CIBERES, Catedra Salud Respiratoria, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Faner","sequence":"additional","affiliation":[{"name":"Respiratory Institute, Clinic Barcelona, FCRB-IDIBAPS, CIBERES, Catedra Salud Respiratoria, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4288-5973","authenticated-orcid":false,"given":"Ian","family":"Pavord","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-6886","authenticated-orcid":false,"given":"Simon","family":"Couillard","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de M\u00e9decine et des Sciences de la Sant\u00e9, Universit\u00e9 de Sherbrooke, Sherbrooke, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Inoue","sequence":"additional","affiliation":[{"name":"Graduate School of Medical and Dental Sciences, Department of Pulmonary Medicine, Kagoshima University, Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-9992","authenticated-orcid":false,"given":"David B","family":"Price","sequence":"additional","affiliation":[{"name":"Observational and Pragmatic Research Institute, Singapore"},{"name":"Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Maria","family":"Olaguibel","sequence":"additional","affiliation":[{"name":"Servicio de Alergolog\u00eda, Hospital Universitario de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huib A M","family":"Kerstjens","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, University Medical Centre Groningen, Groningen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"van den Berge","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, University Medical Centre Groningen, Groningen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The NOVELTY Scientific Community","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"2026042110202179000_thorax-2025-223646v1.1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2023 report). 2023. Available: https:\/\/goldcopd.org"},{"key":"2026042110202179000_thorax-2025-223646v1.2","unstructured":"Global Initiative for Asthma (GINA) . Global strategy for asthma management and prevention. 2022. Available: http:\/\/www.ginasthma.org"},{"key":"2026042110202179000_thorax-2025-223646v1.3","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S312560"},{"key":"2026042110202179000_thorax-2025-223646v1.4","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(17)30217-5","article-title":"Eosinophils in COPD: just another biomarker?","volume":"5","author":"Bafadhel","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026042110202179000_thorax-2025-223646v1.5","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00570-2021","article-title":"Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype Oxford Asthma Attack Risk Scale (ORACLE)","volume":"8","author":"Couillard","year":"2022","journal-title":"ERJ Open Res"},{"key":"2026042110202179000_thorax-2025-223646v1.6","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-217325"},{"key":"2026042110202179000_thorax-2025-223646v1.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916046"},{"key":"2026042110202179000_thorax-2025-223646v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30879-6"},{"key":"2026042110202179000_thorax-2025-223646v1.9","doi-asserted-by":"publisher","DOI":"10.1164\/RCCM.202104-1040LE"},{"key":"2026042110202179000_thorax-2025-223646v1.10","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00616-2018","article-title":"Combined value of exhaled nitric oxide and blood eosinophils in chronic airway disease: the Copenhagen General Population Study","volume":"52","author":"\u00c7olak","year":"2018","journal-title":"Eur Respir J"},{"key":"2026042110202179000_thorax-2025-223646v1.11","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00036-2018","article-title":"Prospective observational study in patients with obstructive lung disease: NOVELTY design","volume":"5","author":"Reddel","year":"2019","journal-title":"ERJ Open Res"},{"key":"2026042110202179000_thorax-2025-223646v1.12","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1590ST"},{"key":"2026042110202179000_thorax-2025-223646v1.13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200406-710ST"},{"key":"2026042110202179000_thorax-2025-223646v1.14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.5937\/jomb0-27945","article-title":"Stability of hematological analytes during 48 hours storage at three temperatures using Cell-Dyn hematology analyzer","volume":"40","author":"Unalli","year":"2021","journal-title":"J Med Biochem"},{"key":"2026042110202179000_thorax-2025-223646v1.15","doi-asserted-by":"crossref","DOI":"10.4102\/ajlm.v4i1.208","article-title":"Prolonged storage-induced changes in haematology parameters referred for testing","volume":"4","author":"Schapkaitz","year":"2015","journal-title":"Afr J Lab Med"},{"key":"2026042110202179000_thorax-2025-223646v1.16","doi-asserted-by":"publisher","DOI":"10.1080\/00031305.2016.1154108"},{"key":"2026042110202179000_thorax-2025-223646v1.17","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11020236","article-title":"Using Blood Eosinophil Count as a Biomarker to Guide Corticosteroid Treatment for Chronic Obstructive Pulmonary Disease","volume":"11","author":"Sivapalan","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"2026042110202179000_thorax-2025-223646v1.18","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.2174\/1389450119666180212120012","article-title":"Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD","volume":"19","author":"Kostikas","year":"2018","journal-title":"Curr Drug Targets"},{"key":"2026042110202179000_thorax-2025-223646v1.19","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jaip.2016.11.007","article-title":"Identifying Risk of Future Asthma Attacks Using UK Medical Record Data: A Respiratory Effectiveness Group Initiative","volume":"5","author":"Blakey","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026042110202179000_thorax-2025-223646v1.20","first-page":"2439","article-title":"Predicting frequent COPD exacerbations using primary care data","volume":"10","author":"Kerkhof","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026042110202179000_thorax-2025-223646v1.21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01457-2017","article-title":"Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD","volume":"51","author":"Alc\u00e1zar-Navarrete","year":"2018","journal-title":"Eur Respir J"},{"key":"2026042110202179000_thorax-2025-223646v1.22","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.152.2.7543345"},{"key":"2026042110202179000_thorax-2025-223646v1.23","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/271918","article-title":"Exhaled nitric oxide as a biomarker in COPD and related comorbidities","volume":"2014","author":"Malerba","year":"2014","journal-title":"Biomed Res Int"},{"key":"2026042110202179000_thorax-2025-223646v1.24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03927-2020"},{"key":"2026042110202179000_thorax-2025-223646v1.25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S2213-2600(17)30424-1","article-title":"Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial","volume":"6","author":"Price","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026042110202179000_thorax-2025-223646v1.26","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202010-1249OC"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2025-223646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:20:40Z","timestamp":1776792040000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2025-223646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":26,"alternative-id":["10.1136\/thorax-2025-223646"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2025-223646","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}